300+ investors in your industry, stage, and region Get
Any industry
Google
Clean Energy
EdTech
Artificial Intelligence
Local
Enterprise Software
Travel
InsurTech
Platforms
Retail
Oil and Gas
Social Impact
Cryptocurrency
SaaS
Film
Restaurants
Photography
Payments
Email
CleanTech
Energy
Marketplace
Organic Food
Fitness
Machine Learning
Health Care
Agriculture (AgTech)
Gaming
Social Network
Facebook
Blockchain
B2B
Video Games
Big Data
Medical Device
Wellness
Education
Mobile
Automotive
Sports
Legal
eSports
Construction
Hospitality
Biotechnology
Consumer
Renewable Energy
Software
Crowdfunding
Theatre
Medical
Recruiting
Venture Capital
Web3
Cannabis
LGBT
Fashion
Celebrity
Climate
Mobile Apps
Life Science
Wine and Spirits
Social
Food and Beverage
Publishing
Music
Art
Real Estate
Beauty
Sporting Goods
Manufacturing
Digital Media
FinTech
Infrastructure
Finance
Financial Services
Social Media
Franchise
Mobile Advertising
Android
Sustainability
Hardware
Biotech
Impact
Proptech
Transportation
Non Profit
Enterprise
Community
Media (Entertainment)
Internet
Any country
Hong Kong
Thailand
United Arab Emirates
Egypt
Greece
Croatia
Burkina Faso
South Korea
Singapore
Gibraltar
Brazil
Liberia
Taiwan
Tunisia
Sweden
Zimbabwe
Zambia
Norway
Tajikistan
Mexico
Nigeria
Russian Federation
Togo
Guinea
Nepal
Iran
Isle of Man
Madagascar
Pakistan
Kyrgyzstan
LATAM
Romania
Africa
Oceania
Puerto Rico
Oman
Poland
Cameroon
Guernsey
Sudan
Andorra
Colombia
Armenia
China
Costa Rica
Czech Republic
Kenya
Kuwait
Marshall Islands
Luxembourg
Malta
Mozambique
Namibia
Mauritius
Nicaragua
Panama
Serbia
Uzbekistan
New Zealand
Australia
Saudi Arabia
Sri Lanka
Jamaica
Switzerland
Guatemala
Kazakhstan
Cayman Islands
Venezuela
Malawi
Myanmar
Uganda
Turkey
Uruguay
Morocco
Seychelles
Moldova
Paraguay
Botswana
Ireland
Japan
South Africa
France
Georgia
Denmark
Ghana
Iraq
Mali
Latvia
Malaysia
Portugal
Philippines
Sierra Leone
Rwanda
El Salvador
Senegal
Tanzania
Canada
Germany
India
United States
Indonesia
Middle East
Dominican Republic
Bermuda
Asia
Albania
Spain
Angola
Europe
Cyprus
Qatar
Argentina
Bangladesh
Belgium
Barbados
Jordan
Austria
Ethiopia
Azerbaijan
Bulgaria
Ecuador
Bahamas
Faroe Islands
Estonia
Jersey
Bahrain
Bolivia
Algeria
Belize
Finland
Italy
Belarus
Hungary
Grenada
Israel
Iceland
Cambodia
Honduras
Lithuania
Liechtenstein
Lebanon
Mongolia
Peru
Slovenia
San Marino
Ukraine
United Kingdom
Vietnam
Chile
Angel Investors
VC Funds
All Investors
Access Full Database - Free Forever
Open database
Toho Holdings, VC Fund

Toho Holdings

VC Fund

Tokyo, Japan

Toho Holdings is a VC fund in Tokyo focused on Medical and Health Care. Toho Holdings focuses on pharmaceutical wholesale business, dispensing pharmacy business, and pharmaceutical manufacturing business. The firm was founded in 1948 and is headquartered in Tokyo, Japan.

Total investments:
14
Last investment:
Lead investor:
14%

Last updated:

Industries Toho Holdings invests in

MedicalHealth CareBiotechnologyNursing and Residential CarePharmaceutical

Stages Toho Holdings invests in

Funding RoundCorporate RoundVenture - Series UnknownSeedGrant

Countries Toho Holdings invests in

JapanSingapore

Round sizes

Venture - Series Unknown $8.8M–$9.5M

Round size

Venture - Series Unknown
$8.8M–$9.5M

Investment Focus

Industry

  • Medical 8 (57%)
  • Health Care 8 (57%)
  • Biotechnology 6 (43%)
  • Nursing and Residential Care 4 (29%)
  • Pharmaceutical 3 (21%)
See all 20 industries →

Stage

  • Funding Round 5 (36%)
  • Corporate Round 3 (21%)
  • Venture - Series Unknown 2 (14%)
  • Seed 1 (7%)
  • Grant 1 (7%)
See all 7 stages →

Country

  • Japan 12 (86%)
  • Singapore 1 (7%)

Investments

CompanyDescriptionRoundLinks
Surv Biopharma Surv Biopharma
Surv Biopharma develops a drug discovery platform that facilitates research and development of veterinary drugs and pharmaceutical products. $14.1M / Series B / Nov 11, 2025
Reborna Biosciences Reborna Biosciences
Reborna Biosciences provides research and development in the field of genetic diseases. The company develops therapeutic options for area of unmet medical needs in genetic rare disease. The company's technology enables low-molecular compounds to target ribonucleic acid. The company provides new disease-modifying drugs for patients sufferingfrom rare genetic diseases including spinal muscular atrophy. $5.3M / Jun 25, 2025
Hirosaki Lifescience Innovation Hirosaki Lifescience Innovation
Hirosaki Lifescience Innovation is engaged in the development, manufacture, and sale of regenerative medicine products. $15.2M / Series C / Jul 22, 2024
United Immunity United Immunity
United Immunity is a research, development, manufacture and sale of pharmaceuticals, mainly for cancer immunotherapy. Sep 11, 2023
United Immunity United Immunity
United Immunity is a research, development, manufacture and sale of pharmaceuticals, mainly for cancer immunotherapy. Grant / Sep 11, 2023
Cellusion Cellusion
Cellusion is a regenerative medicine startup from Keio University. The mission of Cellusion is to deliver novel therapies for all bullous keratopathy patients by our iPS cells origin corneal endothelial cells mass culture system. $9.5M / Venture - Series Unknown / Jan 06, 2022
Aevice Health Aevice Health
Aevice Health provides non-invasive wearable technology that enables real-time monitoring of respiratory health. The devices facilitate early detection of cardiopulmonary issues and allow clinicians to track patient responses to treatment effectively. This approach enhances patient care by delivering critical insights directly from home. $2.1M / Seed / Jun 15, 2021
KUBIX KUBIX
KUBIX is a biotechnology company. Corporate Round / Jan 18, 2021
Entouch Entouch
Entouch provides an environment where doctors can receive explanations of drugs from the MRs whenever it is convenient for them. Corporate Round / Aug 25, 2020
Kringle Pharma Kringle Pharma
Kringle Pharma, Inc., a biopharmaceutical company, develops pharmaceutical products based on its research on hepatocyte growth factor (HGF) and NK4. Its HGF has the regenerative healing ability in regard to liver cells, as well as various cells and organs; and NK4 is a bi-functional molecule, which inhibits the invasion and metastasis of tumorcells as an HGF-antagonist, as well as possesses antiangiogenic activity. The company’s pipeline includes recombinant human HGF for the treatment of acute renal failure, skin ulcers, and CNS diseases; and recombinant human NK4 and NK4 gene drugs for cancer therapy. Kringle Pharma, Inc. was founded in 2001 and is based in Toyonaka, Japan. $8.8M / Venture - Series Unknown / Feb 28, 2020
See all 14 investments →

Co-Investors

Access 48,091 investors

822 industries, 177 countries. Updated daily. Emails and phones included.

Browse database — It's Free!

Find investors for your startup

Search 48,091 investors by industry and country. Emails and phones included.

Any industry
Google
Clean Energy
EdTech
Artificial Intelligence
Local
Enterprise Software
Travel
InsurTech
Platforms
Retail
Oil and Gas
Social Impact
Cryptocurrency
SaaS
Film
Restaurants
Photography
Payments
Email
CleanTech
Energy
Marketplace
Organic Food
Fitness
Machine Learning
Health Care
Agriculture (AgTech)
Gaming
Social Network
Facebook
Blockchain
B2B
Video Games
Big Data
Medical Device
Wellness
Education
Mobile
Automotive
Sports
Legal
eSports
Construction
Hospitality
Biotechnology
Consumer
Renewable Energy
Software
Crowdfunding
Theatre
Medical
Recruiting
Venture Capital
Web3
Cannabis
LGBT
Fashion
Celebrity
Climate
Mobile Apps
Life Science
Wine and Spirits
Social
Food and Beverage
Publishing
Music
Art
Real Estate
Beauty
Sporting Goods
Manufacturing
Digital Media
FinTech
Infrastructure
Finance
Financial Services
Social Media
Franchise
Mobile Advertising
Android
Sustainability
Hardware
Biotech
Impact
Proptech
Transportation
Non Profit
Enterprise
Community
Media (Entertainment)
Internet
Any country
Hong Kong
Thailand
United Arab Emirates
Egypt
Greece
Croatia
Burkina Faso
South Korea
Singapore
Gibraltar
Brazil
Liberia
Taiwan
Tunisia
Sweden
Zimbabwe
Zambia
Norway
Tajikistan
Mexico
Nigeria
Russian Federation
Togo
Guinea
Nepal
Iran
Isle of Man
Madagascar
Pakistan
Kyrgyzstan
LATAM
Romania
Africa
Oceania
Puerto Rico
Oman
Poland
Cameroon
Guernsey
Sudan
Andorra
Colombia
Armenia
China
Costa Rica
Czech Republic
Kenya
Kuwait
Marshall Islands
Luxembourg
Malta
Mozambique
Namibia
Mauritius
Nicaragua
Panama
Serbia
Uzbekistan
New Zealand
Australia
Saudi Arabia
Sri Lanka
Jamaica
Switzerland
Guatemala
Kazakhstan
Cayman Islands
Venezuela
Malawi
Myanmar
Uganda
Turkey
Uruguay
Morocco
Seychelles
Moldova
Paraguay
Botswana
Ireland
Japan
South Africa
France
Georgia
Denmark
Ghana
Iraq
Mali
Latvia
Malaysia
Portugal
Philippines
Sierra Leone
Rwanda
El Salvador
Senegal
Tanzania
Canada
Germany
India
United States
Indonesia
Middle East
Dominican Republic
Bermuda
Asia
Albania
Spain
Angola
Europe
Cyprus
Qatar
Argentina
Bangladesh
Belgium
Barbados
Jordan
Austria
Ethiopia
Azerbaijan
Bulgaria
Ecuador
Bahamas
Faroe Islands
Estonia
Jersey
Bahrain
Bolivia
Algeria
Belize
Finland
Italy
Belarus
Hungary
Grenada
Israel
Iceland
Cambodia
Honduras
Lithuania
Liechtenstein
Lebanon
Mongolia
Peru
Slovenia
San Marino
Ukraine
United Kingdom
Vietnam
Chile
Angel Investors
VC Funds
All Investors

Similar Investors

Recommended lists

FAQ

What does Toho Holdings invest in?

Toho Holdings invests primarily in Medical, Health Care and Biotechnology startups, most often at Funding Round and Corporate Round stage. Most of the 14 investments tracked by Shizune back companies in Japan. The Investment Focus section breaks down every industry, stage and country in the portfolio.

What is Toho Holdings's check size?

Toho Holdings typically joins rounds of $8.8M–$9.5M at Venture - Series Unknown. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Toho Holdings participates in.

When did Toho Holdings last invest?

The most recent investment recorded for Toho Holdings closed in Nov 2025. Shizune tracks 14 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

Contact your first 100 investors today

Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.

Find investors — It's Free!
Toho Holdings Toho Holdings Find emails